Angiogenesis
Angiogenesis inhibitors are compounds that interfere with the formation of new blood vessels, a process critical in cancer growth and metastasis. By inhibiting angiogenesis, these compounds can restrict the blood supply to tumors, slowing or halting their growth. Angiogenesis inhibitors are essential in cancer research and therapeutic development, providing insights into the mechanisms of tumor progression and offering potential treatments for cancer and other angiogenesis-related diseases. At CymitQuimica, we offer a wide range of high-quality angiogenesis inhibitors to support your research in oncology and vascular biology.
Subcategories of "Angiogenesis"
- BTK(166 products)
- Bcr-Abl(117 products)
- EGFR(578 products)
- FAK(72 products)
- FLT(86 products)
- Fibroblast Growth Factor Receptor (FGFR)(179 products)
- JAK(244 products)
- PDGFR(129 products)
- RAAS(89 products)
- Src(82 products)
- Syk(37 products)
- Thrombin(56 products)
- VDA(2 products)
- VEGFR(242 products)
Show 6 more subcategories
Found 2369 products of "Angiogenesis"
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
Simotinib hydrochloride
CAS:Simotinib hydrochloride: selective oral EGFR inhibitor, IC50 19.9 nM, potent anticancer agent.Formula:C25H27Cl2FN4O4Color and Shape:SolidMolecular weight:537.41EGFR-IN-93
EGFR-IN-93 (compound 18) is an allosteric inhibitor of the T790M/L858R double mutant EGFR. It is applicable for research in non-small cell lung cancer (NSCLC).Formula:C22H18FN3O3Molecular weight:391.13322DP-C-4
DP-C-4 is a Cereblon-based dual PROTAC for simultaneous degradation of EGFR and PARP[1].Color and Shape:LiquidSecretin, canine
CAS:Secretin: endocrine hormone, increases bicarbonate-rich pancreatic fluid, regulates canine gastric functions via Src kinase pathway.Formula:C131H222N44O41Purity:98%Color and Shape:SolidMolecular weight:3069.43PRMT5/EGFR-IN-1
PRMT5/EGFR-IN-1 (Compound 10p) is an orally active dual inhibitor targeting PRMT5 and EGFR, with IC50 values of 15.47 μM and 19.31 μM, respectively. It demonstrates antiproliferative activity against the A549, MCF7, HeLa, and MDA-MB-231 cell lines. This compound also exhibits favorable pharmacokinetic (PK) and pharmacodynamic (PD) properties in vivo and significantly inhibits the growth of MCF7 orthotopic xenograft tumors.Formula:C27H22F6N2O2Molecular weight:520.15855MS39N
CAS:MS39N (compound 27) serves as the negative control for MS39, capable of binding to EGFR without causing its degradation.Formula:C55H71ClFN9O7SMolecular weight:1056.73HER2-IN-13
CAS:HER2-IN-13 (Compound 33) serves as an effective HER2 inhibitor, exhibiting an IC50 value of 8 nM, and additionally demonstrates inhibition of wt-EGFR with anFormula:C26H23ClF2N8O3Color and Shape:SolidMolecular weight:568.96Wu-5
CAS:Wu-5 is a potent USP10 inhibitor that inhibits FLT3 and AMPK pathways, promoting the breakdown of FLT3-ITD and inducing apoptosis.Formula:C15H13NO7SPurity:99.65%Color and Shape:SoildMolecular weight:351.33DA5-HTL
DA5-HTL is a compound that combines dasatinib with the HaloTag system, effectively inhibiting the growth of tumor cells, with a GI50 of 1.923 nM.Formula:C39H58Cl2N8O8SMolecular weight:868.34754Lyn peptide inhibitor
CAS:Inhibits Lyn kinase, blocks IL-5 receptor, prevents eosinophil differentiation and reduces asthma-related inflammation in mice.Formula:C115H184N30O24Purity:98%Color and Shape:SolidMolecular weight:2370.91EGFR-IN-131
EGFR-IN-131 (compound 3a) is an efficacious EGFR inhibitor capable of crossing the blood-brain barrier, with an IC50 value of 272.9 nM. This compound exhibits anti-proliferative activity, induces cellular apoptosis (apoptosis), and causes cell cycle arrest in the G0/G1 phase. Additionally, EGFR-IN-131 reduces the protein expression of p-EGFR.Formula:C26H23FN4O2SColor and Shape:SolidMolecular weight:474.55VEGFR-2-IN-31
VEGFR-2-IN-31 (compound 3i), a robust VEGFR-2 inhibitor (IC50=8.93 nM), serves as an anti-prostate cancer agent by arresting the cell cycle at the S-phase andFormula:C15H10F2N4OPurity:98%Color and Shape:SolidMolecular weight:300.26PROTAC FLT3/CDK9 degrader-1
Potent PROTAC degrader for FLT3/CDK9, induces apoptosis, and shows promise for FLT3-ITD mutated AML research.Formula:C48H62N12O7Color and Shape:SolidMolecular weight:919.08Self-assembling peptide pY1
Self-assembling peptide pY1, which aggregates around cancer cells, specifically targets the EGFR receptor. When co-cultured with Ovalbumin (OVA), pY1 effectively inhibits the endocytosis of OVA.Formula:C104H125N24O29PColor and Shape:SolidMolecular weight:2206.22PKCε (85-92)
CAS:PKCε (85-92) (ψεRACK) is a peptide and selective PKCε activator, induces a pro-angiogenic response, promotes FGF-2 cytosolization, regulates VEGF activity.Formula:C39H54N10O14Purity:98.71%Color and Shape:SolidMolecular weight:886.91FLT3-IN-24
FLT3-IN-24 (compound 24) is a potent and selective inhibitor of FLT3 kinase, with an IC50 of 7.94 nM. It also exhibits anti-proliferative effects on cells.Formula:C23H20N6O2SMolecular weight:444.13685VEGFR-2-IN-35
VEGFR-2-IN-35 (compound 7) is a potent inhibitor of VEGFR-2, exhibiting an IC50 of 37 nM.Formula:C25H19N3O3Purity:98%Color and Shape:SolidMolecular weight:409.44FGFR4-IN-19
FGFR4-IN-19 (compound 8B) is a potent covalent inhibitor of fibroblast growth factor receptor 4 (FGFR4) with an IC50 value of 1.2 nM. It achieves high efficiency and selectivity by covalently targeting the rare cysteine (C552) in the FGFR4 kinase domain. FGFR4-IN-19 is applicable for hepatocellular carcinoma (HCC) research.Formula:C21H14Cl3N5O4Molecular weight:505.01114SOS1/EGFR-IN-2
SOS1/EGFR-IN-2 (Compound 4) functions as a dual inhibitor of SOS1 and EGFR, exhibiting IC50 values of 8.3 and 14.6 nM, respectively. It demonstrates significant antiproliferative effects on cancer cells harboring various KRAS mutations.Formula:C25H29F3N4O3Color and Shape:SolidMolecular weight:490.52PROTAC EGFR degrader 3
CAS:Potent PROTAC EGFR degrader 3; excellent against H1975/HCC827 cells; lysosome-involved mutant degradation.Formula:C60H77N13O5SColor and Shape:SolidMolecular weight:1092.4MR44397
MR44397 is a ligand for WD40 repeat (WDR) 5 and is applicable in cancer research.Formula:C23H26N4O2SColor and Shape:SolidMolecular weight:422.54SJ1008030
CAS:SJ1008030, a JAK2 PROTAC, degrades JAK2; EC50: 5.4 nM, IC50: 32.09 nM in MHH-CALL-4 cells for leukemia research.
Formula:C42H43N13O7SColor and Shape:SolidMolecular weight:873.94JAK 3 inhibitor IV
CAS:JAK 3 inhibitor IV (ZM 39923 hydrochloride) is a JAK1/3 inhibitor with pIC50 of 4.4/7.1, almost no activity to JAK2 and modestly potent to EGFR; also found toFormula:C16H19NOPurity:98%Color and Shape:SolidMolecular weight:241.33Arginyl-Glutamine
CAS:Arginyl-Glutamine (Arg-Gln) is a dipeptide nutritional supplement that protects neonatal mice from hyperoxia-induced lung injury, lowering VEGF levels.Formula:C11H22N6O4Purity:95.2%Color and Shape:SolidMolecular weight:302.33Kanglexin
CAS:Kanglexin is an orally active novel anthraquinone compound. It inhibits NLRP3 inflammasome activation and pyroptosis, offering cardioprotective benefits. By stimulating the FGFR1/ERK signaling pathway, Kanglexin promotes angiogenesis and accelerates wound healing in diabetes. Additionally, it has lipid-lowering effects and inhibits vascular smooth muscle cell dedifferentiation, making it a potential compound for studying hyperlipidemia, fatty liver, and atherosclerosis.Formula:C21H18O8Molecular weight:398.36BR-cpd7
BR-cpd7 is a PROTAC degrader of fibroblast growth factor receptors (FGFR1/2) with a DC50 of 10 nM. It is capable of arresting the cell cycle and inhibiting the proliferation of tumor cells with aberrant activation of FGFR1/2.Formula:C44H47Cl2N11O8Molecular weight:927.29861BTK-IN-40
CAS:BTK-IN-40 (compound 375) is an inhibitor of BTK.Formula:C20H25N7O2Color and Shape:SolidMolecular weight:395.46JAK-IN-40
JAK-IN-40 (Compound 46) is an inhibitor of JAK, effectively targeting JAK1, JAK2, and JAK3 with IC50 values of 0.022, 0.759, and 1.601 μM, respectively. It reduces the phosphorylation of STAT3 and inhibits the proliferation of cancer cells Ba/F3 and JAK1-TEL Ba/F3 with GI50 values of 0.614 μM and 0.193 μM. JAK-IN-40 arrests cell cycle progression at the G2/M phase in H1975 and H2087 cells, leading to apoptosis. Additionally, JAK-IN-40 exhibits a synergistic anti-tumor effect when used in combination with Osimertinib.Formula:C26H32N8O3SColor and Shape:SolidMolecular weight:536.65PROTAC BTK Degrader-5
PROTAC BTK Degraders-5 (Compound 3e) is a selective Bruton's tyrosine kinase (BTK) degrader with a DC50 of 7.0 nM in JeKo-1 cells, demonstrating specificity byFormula:C52H57ClFN9O6Purity:98%Color and Shape:SolidMolecular weight:958.52GSK-1070916
CAS:GSK-1070916 (GSK-1070916A) is a reversible and ATP-competitive inhibitor of Aurora B/C with IC50 of 3.5 nM/6.5 nM.Formula:C30H33N7OPurity:99.73%Color and Shape:SolidMolecular weight:507.63Tyrosinase-IN-16
CAS:Tyrosinase-IN-16 inhibited tyrosinase.Formula:C8H6BrN3SPurity:99.94%Color and Shape:SolidMolecular weight:256.12SNIPER(ABL)-047
SNIPER(ABL)-047, a compound that links HG-7-85-01 (an ABL inhibitor) to MV-1 (an IAP ligand) via a linker, effectively decreases the BCR-ABL protein levels,Formula:C67H82F3N11O9SPurity:98%Color and Shape:SolidMolecular weight:1274.5SJF 1521
CAS:SJF 1521 is an EGFR degrader belonging to the PROTAC class that selectively degrades EGFR while preserving HER2.Formula:C57H61ClFN7O9SPurity:99.20%Color and Shape:SolidMolecular weight:1074.65FDU73
FDU73 is a potent and selective BTK PROTAC degrader with a DC50 of 2.9 nM in JeKo-1 cells. It inhibits tumor cell proliferation and exhibits antitumor activity.Color and Shape:Odour SolidVEGFR-2-IN-36
VEGFR-2-IN-36 (compound 15) serves as a potent VEGFR-2 inhibitor, exhibiting an IC50 value of 0.067 μM, and acts as an apoptosis inducer with demonstratedFormula:C24H23N7O5Purity:98%Color and Shape:SolidMolecular weight:489.48VEGFR2/HDAC1-IN-1
VEGFR2/HDAC1-IN-1 (compound 13) is a potent dual inhibitor of VEGFR-2 and HDAC, with IC50 values of 57.83 nM for VEGFR-2 and 9.82 nM for HDAC.Purity:98%Color and Shape:Odour SolidM4205
CAS:M4205 is an inhibitor of c-Kit exhibiting high activity on c-Kit mutations in exons 11, 13, 17.Formula:C29H32N8OPurity:99.07%Color and Shape:SolidMolecular weight:508.62Ref: TM-T9689
1mg50.00€5mg110.00€10mg170.00€25mg290.00€50mg414.00€100mg572.00€200mg772.00€1mL*10mM (DMSO)122.00€CN009543V
CAS:CN009543V is an enhancer of tyrosine phosphorylation of EGFR via downstream signaling pathways.Formula:C12H12N4O6SColor and Shape:SolidMolecular weight:340.31CNX-500
CAS:CNX-500: covalent Btk inhibitor linked to biotin, IC50 0.5 nM, low effect on EGFR and Src kinases.Formula:C48H68N10O9SPurity:98%Color and Shape:SolidMolecular weight:961.18TL13-112
CAS:TL13-112 is a selective degrader of ALK-PROTAC and inhibits ALK activity (IC50: 0.14 nM).Formula:C49H60ClN9O10SPurity:98%Color and Shape:SolidMolecular weight:1002.57MC-Val-Cit-PAB-Amide-TLR7 agonist 4
CAS:MC-Val-Cit-PAB-Amide-TLR7 agonist 4 Conjugate is a conjugate formed by linking MC-Val-Cit-PAB-Amide and TLR7 agonist 4, useful for cancer research.Formula:C52H72N12O11Purity:97.70%Color and Shape:SolidMolecular weight:1041.2SIAIS100
SIAIS100, a potent BCR-ABL PROTAC degrader, demonstrates a DC50 value of 2.7 nM, highlighting its efficacy.Formula:C44H50ClF2N9O5SColor and Shape:SolidMolecular weight:890.44SJ10542
CAS:SJ10542: potent JAK2/3-targeting PG-PROTAC; DC50s: JAK2 - 14 nM, JAK3 - 11 nM, JAK2-fusion ALL - 24 nM; CRBN recruiter.Formula:C41H46N12O5SColor and Shape:SolidMolecular weight:818.95BCR-ABL-IN-3
CAS:BCR-ABL-IN-3 irreversibly inhibits Bcr-Abl with <100 nM IC50, showing significant anti-cancer effects.Formula:C20H17ClF2N4O3SColor and Shape:SolidMolecular weight:466.89SC209
CAS:SC209, a STRO-002 metabolite from patent WO2021247798, synthesizes anti-EGFR ADCs.Formula:C27H44N4O4Color and Shape:SolidMolecular weight:488.66DBt-10
DBt-10 is a potent Bruton's tyrosine kinase (BTK) degrader [1].Formula:C68H86ClFN16O6Purity:98%Color and Shape:SolidMolecular weight:1277.96SNIPER(ABL)-024
CAS:SNIPER(ABL)-024, a compound that conjugates GNF5 (ABL inhibitor) to an LCL161 derivative (IAP ligand) via a linker, effectively reduces BCR-ABL protein levels,Formula:C52H61F3N8O9SPurity:98%Color and Shape:SolidMolecular weight:1031.15FLT3-IN-20
FLT3-IN-20 (compound 34f) is a potent FLT3 inhibitor, demonstrating IC50 values of 1 nM for FLT3-D835Y and 4 nM for FLT3-ITD.Formula:C28H33N7O2SColor and Shape:SolidMolecular weight:531.67SPP-037
SPP-037 is an orally active selective inhibitor of ST6GAL1, with an IC50 of 3.59 μM. It exhibits anti-migration activity against MDA-MB-231 cells by inhibiting integrin α2,6-sialylation and the integrin-FAK-paxillin pathway. In MDA-MB-231 xenograft mouse models, SPP-037 demonstrates antitumor properties. This compound is applicable in breast cancer research.Formula:C36H50ClN3O9SColor and Shape:SolidMolecular weight:735.29563JAK-IN-15
CAS:JAK-IN-15 is a JAK inhibitor. WO2016119700A1 (Compound 15).Formula:C22H23FN4O3SColor and Shape:SolidMolecular weight:442.51
